U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939555) titled 'Personalized Antisense Oligonucleotide Therapy for Participants With Progressive Axonal Neuropathy Due to SLC12A6 Mutation' on Nov. 04.
Brief Summary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with axonal neuropathy due to a mutation in the SLC12A6 gene.
Study Start Date: Sept. 25
Study Type: INTERVENTIONAL
Condition:
Progressive Axonal Neuropathy
Intervention:
DRUG: nL-SLC12-001
Personalized antisense oligonucleotide
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: n-Lorem Foundation
Disclaimer: Curated by HT Syndication....